SG Analytics (SGA) assists the client in generating evidence of the value of a new drug or product for reimbursement and healthcare payers by employing AI/ML tools to derive crisp and precise solutions.
HEOR is undertaken to analyze DALY and positive health outcomes by studying healthcare providers, hospitals, clinics, managed care, and public health promotion activities across different set-ups.
SGA started its health economics and outcomes research (HEOR) services and solutions in 2020. As one of the most sought-after service providers for our pharmaceutical clients, our health economics and outcomes research consultants employ ML tools to scrape precise real-world data pertinent to medical research and disease areas and transform the process into a much easier, white-labeled customized report.
With each passing day, there has been an increase in the relevance of HEOR, as it facilitates valuable information to the decision-makers in drug, diagnostics, and medical product companies, and healthcare providers and patients for optimal allocation of healthcare resources. Health economics outcomes research is a function within a pharma or life sciences company that offers assistance to strategy and marketing teams to generate evidence of the value of a new drug or diagnostic kit or product, or other intervention which will need reimbursement in the future. Millions of dollars are being spent to generate cumbersome HEOR reports from the market.
Why SGA
Industry Leaders
SGA thrives by its brand promise Life is Possible, and is recognized as the trusted healthcare market research consulting company.
12+ Languages
Language capabilities include Mandarin, Cantonese, Korean, German, Spanish, Arabic, Bahasa, Hindi, Bengali, and English (US/UK).
Data-Driven Insights
With in-depth domain knowledge and proven capabilities of delivering monetizable insights, we deliver high-quality, efficient outputs.
End-To-End Solutioning
The in-house KOL (key opinion leader) capability of more than 700, along with analytical and ML/AI capabilities, helps in presenting credible competitive information.
White Papers
Market Entry in 2023: Why Must You Also Look at Markets Other Than the US and Japan?
Due to dollar fluctuations and the likelihood of market recession, investors and manufacturers of medical devices and pharma are exploring new opportunities...
White Papers
The Blue Ocean Strategy in the Pharmaceutical Industry: What Is the Blue Ocean Strategy About?
Blue ocean refers to a new market that presents low competition, is less crowded, and is open to accommodate new innovations and marketing opportunities....
White Papers
What Happens When You Invest in Healthcare Consulting and Analytics?
Healthcare providers who are struggling with high-volume complex data are feeling the need for assistance with data convergence and management. With...
We strongly believe in women power. Our research team consists of more females than males i.e., 55 % females, and consists of PhDs, M Pharms, D Pharms, Postgraduate in finance, Biotech postgraduates, and MBAs.
